Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Theravance Biopharma Inc Stock Research

TBPH

9.06USD+0.07(+0.78%)Market Closed
Watchlist

Market Summary

USD9.06+0.07
Market Closed
0.78%

TBPH Alerts

TBPH Stock Price

TBPH RSI Chart

TBPH Valuation

Market Cap

486.5M

Price/Earnings (Trailing)

0.56

Price/Sales (Trailing)

9.49

EV/EBITDA

-5.98

Price/Free Cashflow

-2.86

TBPH Price/Sales (Trailing)

TBPH Profitability

EBT Margin

-125.52%

Return on Equity

236.4%

Return on Assets

162.66%

Free Cashflow Yield

-34.91%

TBPH Fundamentals

TBPH Revenue

Revenue (TTM)

51.3M

Revenue Y/Y

24.43%

Revenue Q/Q

31.99%

TBPH Earnings

Earnings (TTM)

868.5M

Earnings Y/Y

-91%

Earnings Q/Q

29.17%

Price Action

52 Week Range

8.7612.03
(Low)(High)

Last 7 days

-8.2%

Last 30 days

-4.6%

Last 90 days

-16.2%

Trailing 12 Months

-11.3%

TBPH Financial Health

Current Ratio

9.98

TBPH Investor Care

Buy Backs (1Y)

29.60%

Diluted EPS (TTM)

11.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for TBPH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-14
GRAHAM RICHARD A
sold
-24,547
9.89
-2,482
svp, research & development
2023-08-22
Farnum Rhonda
sold
-17,112
9.47
-1,807
svp, comm & medical affairs
2023-08-20
Winningham Rick E
sold (taxes)
-153,299
9.7
-15,804
chief executive officer
2023-08-20
Sawaf Aziz
sold (taxes)
-69,005
9.7
-7,114
svp & chief financial officer
2023-08-20
GRAHAM RICHARD A
sold (taxes)
-101,472
9.7
-10,461
svp, research & development
2023-08-20
Grimaud Brett A.
sold (taxes)
-86,446
9.7
-8,912
svp, gen counsel and secretary
2023-08-20
Farnum Rhonda
sold (taxes)
-101,462
9.7
-10,460
svp, comm & medical affairs
2023-08-11
GRAHAM RICHARD A
sold
-23,196
9.99
-2,322
svp, research & development
2023-07-14
GRAHAM RICHARD A
sold
-22,848
9.84
-2,322
svp, research & development
2023-06-14
GRAHAM RICHARD A
sold
-24,822
10.69
-2,322
svp, research & development

1–10 of 50

Which funds bought or sold TBPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-21
OSAIC HOLDINGS, INC.
unchanged
-
-69.00
1,428
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.32
-72,150
672,854
-%
2023-08-16
Nuveen Asset Management, LLC
added
1.82
-48,645
1,628,360
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
1.24
-125,033
3,525,200
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
81.07
106,366
252,623
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
unchanged
-
-38,868
804,557
-%
2023-08-14
Bleakley Financial Group, LLC
new
-
245,295
245,295
0.01%
2023-08-14
CANTOR FITZGERALD, L. P.
unchanged
-
-10,000
207,000
-%
2023-08-14
Graham Capital Management, L.P.
reduced
-18.23
-42,789
151,751
-%
2023-08-14
PDT Partners, LLC
reduced
-0.25
-43,282
850,335
0.12%

1–10 of 46

Latest Funds Activity

Are funds buying TBPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TBPH
No. of Funds

Schedule 13G FIlings of Theravance Biopharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 14, 2023
weiss asset management lp
14.%
7,457,060
SC 13D/A
Jul 10, 2023
baupost group llc/ma
12.84%
7,419,226
SC 13G/A
Apr 12, 2023
weiss asset management lp
11.%
7,457,060
SC 13D
Feb 14, 2023
madison avenue partners, lp
10.4%
7,012,226
SC 13G/A
Feb 14, 2023
orbimed advisors llc
0%
0
SC 13G/A
Feb 13, 2023
baupost group llc/ma
16.95%
11,419,226
SC 13G/A
Feb 09, 2023
vanguard group inc
8.25%
5,558,839
SC 13G/A
Jan 30, 2023
barclays plc
5.00%
3,371,298
SC 13G
Sep 20, 2022
gsk plc
0.0%
0
SC 13D/A
Jun 16, 2022
weiss asset management lp
8.09%
6,157,360
SC 13G

Recent SEC filings of Theravance Biopharma

View All Filings
Date Filed Form Type Document
Sep 18, 2023
4
Insider Trading
Sep 14, 2023
144
Notice of Insider Sale Intent
Sep 12, 2023
8-K
Current Report
Aug 24, 2023
4
Insider Trading
Aug 22, 2023
4
Insider Trading
Aug 22, 2023
4
Insider Trading
Aug 22, 2023
4
Insider Trading
Aug 22, 2023
4
Insider Trading
Aug 22, 2023
4
Insider Trading
Aug 15, 2023
4
Insider Trading

TBPH Fair Value

Loading...

Peers (Alternatives to Theravance Biopharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
512.5B
29.5B
3.56% 89.32%
78.88
17.36
1.53% 14.16%
423.3B
97.8B
-2.65% 0.10%
32.43
4.33
2.29% -28.92%
272.8B
58.3B
-2.13% 26.48%
17.88
4.63
2.00% -81.24%
189.8B
77.9B
-9.16% -24.26%
8.84
2.44
-23.04% -26.74%
150.1B
45.2B
-5.06% -15.06%
23.72
3.25
-4.15% 20.34%
MID-CAP
4.5B
4.6B
-11.49% -16.32%
-66.69
0.98
6.60% 42.04%
SMALL-CAP
2.2B
12.9M
4.30% 396.62%
-19.28
169.83
824.37% 0.76%
1.9B
627.1M
-7.75% -1.79%
-1.34
3.1
-0.20% -204.67%
1.6B
669.2M
-8.68% -37.33%
-350.4
2.39
8.94% -111.64%
830.8M
109.5M
21.79% -27.57%
-5.79
7.59
-2.66% -32.13%
486.5M
51.3M
-4.63% -11.35%
0.56
9.49
-2.14% 955.88%
480.0M
453.3M
110.37% -71.69%
-0.39
1.06
-16.04% 55.90%
100.9M
29.7M
-47.86% -91.50%
-0.59
3.39
-56.77% -25.62%

Theravance Biopharma News

Simply Wall St
Selling Theravance Biopharma Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders.
Simply Wall St,
3 days ago
Seeking Alpha
Investopedia
Top Stocks for August 2023.
Investopedia,
51 days ago
MarketBeat
Lowest PE Ratio Stocks 2023.
MarketBeat,
2 months ago
Investopedia
Top Growth Stocks for July 2023.
Investopedia,
2 months ago
Investopedia
Top Stocks for July 2023.
Investopedia,
2 months ago
Investopedia
Top Healthcare Stocks for June 2023.
Investopedia,
3 months ago
Investopedia
Top Small-Cap Stocks for June 2023.
Investopedia,
3 months ago

Returns for TBPH

Cumulative Returns on TBPH

-17.7%


7-Year Cumulative Returns

-20.8%


5-Year Cumulative Returns

-20.2%


3-Year Cumulative Returns

Risks for TBPH

What is the probability of a big loss on TBPH?

87.3%


Probability that Theravance Biopharma stock will be more than 20% underwater in next one year

81.9%


Probability that Theravance Biopharma stock will be more than 30% underwater in next one year.

53.1%


Probability that Theravance Biopharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TBPH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Theravance Biopharma was unfortunately bought at previous high price.

Drawdowns

Financials for Theravance Biopharma

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue5.6%51,266,00048,567,00051,346,00051,643,00052,386,00054,250,00055,311,00059,095,00064,158,00066,252,00071,857,00082,626,00076,796,00087,938,00073,414,00059,652,00060,063,00057,389,00060,370,00049,148,00040,585,000
Operating Expenses-3.5%118,877,000123,156,000138,246,000177,278,000222,492,000265,365,000313,095,000337,202,000365,265,000375,425,000369,614,000374,465,000357,221,000338,663,000325,329,000303,616,000301,276,000304,830,000299,121,000304,454,000290,438,000
  S&GA Expenses4.5%70,706,00067,650,00067,073,00071,857,00076,879,00086,588,00099,296,000107,705,000113,907,000112,756,000108,531,000111,652,000109,773,000107,220,000106,081,00098,492,00094,760,00097,540,00097,058,000101,124,000100,178,000
  R&D Expenses-10.2%48,565,00054,064,00063,392,00079,270,000113,142,000149,311,000193,657,000227,596,000251,228,000262,539,000260,953,000262,813,000247,448,000231,443,000219,248,000204,492,000205,179,000207,401,000201,348,000200,131,000186,781,000
EBITDA100.0%--46,432,000-86,446,00023,601,000-6,096,000-98,876,000-152,688,000-187,718,000-226,122,000-233,091,000-238,477,000-240,446,000-234,384,000-214,663,000-206,340,000------
EBITDA Margin100.0%--0.96-1.680.46-0.12-1.82-2.76-3.18-3.52-3.52-3.32-2.91-3.05-2.44-2.81------
Interest Expenses-32.8%3,213,0004,782,0006,369,0007,956,0008,547,00018,022,0008,547,0001,263,00010,700,00010,479,0008,547,00040,940,00037,435,00033,945,00031,862,00027,898,00021,967,00016,203,00010,482,0008,548,0008,547,000
Earnings Before Taxes11.4%-66,952,000-75,563,000-92,815,000-136,522,000-176,416,000-206,243,000-265,222,000-272,033,000-289,666,000-299,889,000-303,343,000-284,861,000-275,294,000-252,083,000-241,677,000-229,562,000-225,671,000-233,642,000-226,085,000-252,576,000-258,493,000
EBT Margin100.0%--1.26-1.81-0.81-1.56-2.68-3.61-3.97-4.25-4.27-3.99-3.45-3.58-2.87-3.29------
Net Income-0.9%868,536,000875,990,000872,132,000850,460,000-101,479,000-145,693,000-199,426,000-225,826,000-264,161,000-274,643,000-278,017,000-285,189,000-269,977,000-246,928,000-236,455,000-221,035,000-222,037,000-223,017,000-215,524,000-252,260,000-259,704,000
Net Income Margin-100.0%-18.0416.9916.47-1.94-2.69-3.61-3.82-4.12-4.15-3.87-3.45-3.52-2.81-3.22------
Free Cashflow100.0%--172,143,000-186,991,000-105,370,000-128,679,000-164,062,000-207,858,000-230,349,000-261,934,000-267,302,000-252,538,000-251,965,000-219,556,000-214,240,000-240,332,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-17.1%447539607763361355375403429375469512564605409445492531560371421
  Current Assets-26.5%192261353512155205250297333293393451498534338356426467533333387
    Cash Equivalents-43.7%10618829841987.0094.0091.0012120511481.0093.0010533359.00102178223379101104
  Inventory--------------------18.0018.00
  Net PPE-21.1%10.0012.0012.0012.0013.0013.0014.0016.0017.0017.0016.0015.0014.0014.0013.0012.0013.0013.0013.0012.0011.00
  Current Liabilities-6.3%25.0026.0029.0014233.0044.0059.0066.0067.0086.0012410410798.0011210911011499.0010293.00
Shareholder's Equity-24.4%280371442481-349-351-338-------------34.00
  Retained Earnings-1.8%-891-876-853-843-1,760-1,751-1,726-1,694-1,658-1,606-1,526-1,468-1,394-1,331-1,248-1,182-1,124-1,084-1,012-961-902
  Additional Paid-In Capital-6.0%1,1721,2471,2961,3241,4101,4011,3871,3701,3581,2331,2231,2071,1921,1731,0251,000987972961949937
Shares Outstanding-11.3%54.0061.0065.0067.0076.0075.0074.0074.0066.0064.0064.0063.0061.0059.0057.0056.0055.0055.0054.0054.0054.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations1.3%-169-172-186-105-128-164-207-230-261-265-250-249-217-212-238-226-230-243-112-104-118
  Share Based Compensation-10.7%29.0032.0040.0050.0056.0061.0062.0061.0062.0064.0063.0071.0069.0064.0060.0048.0047.0050.0051.0057.0056.00
Cashflow From Investing0.3%1,0831,0791,1541,12614.0043.0012416626856.0011.00-27.59-11758.00-83.052.0073.0011617711987.00
Cashflow From Financing-9.9%-894-813-758-723-3.4410292.0092.0094.00-9.632632612622641.00232232225225-3.77-4.24
  Buy Backs7.8%265246129376-----------------

TBPH Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 13,749$ 11,050$ 24,166$ 24,246
Expenses:    
Research and development (1)[1]9,42514,92423,99738,177
Selling, general and administrative (1)[1]19,27816,22238,46134,064
Restructuring and related expenses (1)[1]1,1693,0052,74312,329
Total expenses29,87234,15165,20184,570
Loss from operations(16,123)(23,101)(41,035)(60,324)
Interest expense(568)(2,137)(1,118)(4,274)
Interest income and other income (expense), net2,5042,4405,4832,065
Loss from continuing operations before income taxes(14,187)(22,798)(36,670)(62,533)
Provision for income tax (expense) benefit(1,458)5(1,063)(519)
Net loss from continuing operations(15,645)(22,793)(37,733)(63,052)
Income from discontinued operations before income taxes 14,602 28,915
Provision for income tax expense
Net income from discontinued operations 14,602 28,915
Net loss(15,645)(8,191)(37,733)(34,137)
Net unrealized loss on available-for-sale investments(337)(17)(271)(45)
Total comprehensive loss$ (15,982)$ (8,208)$ (38,004)$ (34,182)
Net income (loss) per share:    
Continuing operations - basic$ (0.28)$ (0.30)$ (0.63)$ (0.83)
Continuing operations - diluted(0.28)(0.30)(0.63)(0.83)
Discontinued operations - basic 0.19 0.38
Discontinued operations - diluted 0.19 0.38
Net loss - basic(0.28)(0.11)(0.63)(0.45)
Net loss - diluted$ (0.28)$ (0.11)$ (0.63)$ (0.45)
Shares used to compute net income (loss) per share - basic56,68276,27059,79175,761
Shares used to compute net income (loss) per share - diluted56,68276,27059,79175,761
Total share-based compensation expense$ 6,264$ 9,709$ 13,285$ 24,254
Research and development    
Expenses:    
Restructuring and related expenses (1)1,2001,0002,7005,700
Net income (loss) per share:    
Total share-based compensation expense1,8552,9094,2967,439
Selling, general and administrative    
Expenses:    
Restructuring and related expenses (1) 2,000 6,600
Net income (loss) per share:    
Total share-based compensation expense4,4095,0308,63210,528
Restructuring and related expenses    
Net income (loss) per share:    
Total share-based compensation expense 1,7703576,287
Viatris collaboration agreement    
Revenue:    
Total revenue13,74310,87824,15421,565
Collaboration revenue    
Revenue:    
Total revenue$ 6$ 172$ 12181
Licensing revenue    
Revenue:    
Total revenue   $ 2,500
[1]Amounts include share-based compensation expense as follows:

TBPH Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 105,596$ 298,172
Short-term marketable securities61,85529,312
Receivables from collaborative arrangements15,79616,785
Prepaid clinical and development services9791,513
Other prepaid and current assets7,7777,682
Total current assets192,003353,464
Property and equipment, net9,55311,875
Operating lease assets38,45340,126
Future contingent milestone and royalty assets194,200194,200
Restricted cash836836
Other assets11,5856,899
Total assets446,630607,400
Current liabilities:  
Accounts payable1,5691,554
Accrued personnel-related expenses5,37110,314
Accrued clinical and development expenses4,0064,932
Accrued general and administrative expenses2,8744,020
Operating lease liabilities9,1606,753
Deferred revenue2424
Other accrued liabilities1,5421,118
Total current liabilities24,54628,715
Long-term operating lease liabilities42,52145,407
Future royalty payment contingency26,55625,438
Long-term deferred revenue181192
Unrecognized tax benefits64,98764,191
Other long-term liabilities7,6781,657
Commitments and contingencies
Shareholders' Equity  
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 53,694 and 65,227 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively11
Additional paid-in capital1,172,0901,295,725
Accumulated other comprehensive loss(286)(15)
Accumulated deficit(891,644)(853,911)
Total shareholders' equity280,161441,800
Total liabilities and shareholders' equity$ 446,630$ 607,400
Rick E. Winningham
160
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.